['Previous studies have demonstrated the accumulation of advanced glycation end products (AGE) in patients with chronic renal failure (CRF), but the mechanism is not completely understood. This study was performed to elucidate the effect of heparin on binding of AGE to its receptors on human monocytes.', 'Human serum albumin (HSA) modified with AGE was prepared in vitro and was radioiodinated with carrier-free [(125)I]. Human peripheral blood monocytes obtained from dialysis patients and normal volunteers were isolated by Ficoll-hypaque centrifugation technique. Specific binding (125)I-AGE-HSA to the AGE-receptor on human monocytes was measured by radioactive ligand-receptor binding assay.', 'The binding of (125)I-AGE-HSA to its receptors in dialysis patients was inhibited by 27% 15 minutes after starting of hemodialysis using heparin as anti-coagulant. These effects continued 6 hours and resume to the levels of predialysis after 24 hours. There was no differences in binding of (125)I-AGE-HSA to monocytes between pre-and post-dialysis session when low-molecule weight heparin (LMWH) was used as the anti-coagulant. In vitro study further demonstrated that exposure of normal monocytes to heparin-containing media inhibited the binding of (125)I-AGE-HSA to its receptor with a dose-dependent manner. LMWH did not inhibit such binding.'] Does [ Heparin block the binding of advanced glycation end products to its receptors on human monocytes ]?